journal article·2019-08-16Open access

Dissecting and rebuilding the glioblastoma microenvironment with engineered materials

Kayla J. Wolf, Joseph Chen, Jason D. Coombes, Manish K. Aghi, Sanjay Kumar

Nature Reviews Materials· Volume 4· Issue 10

Abstract

Glioblastoma (GBM) is the most aggressive and common form of primary brain cancer. Several decades of research have provided great insight into GBM progression; however, the prognosis remains poor with a median patient survival time of ~ 15 months. The tumour microenvironment (TME) of GBM plays a crucial role in mediating tumour progression and thus is being explored as a therapeutic target. Progress in the development of treatments targeting the TME is currently limited by a lack of model systems that can accurately recreate the distinct extracellular matrix composition and anatomic features of the brain, such as the blood-brain barrier and axonal tracts. Biomaterials can be applied to develop synthetic models of the GBM TME to mimic physiological and pathophysiological features of the brain, including cellular and ECM composition, mechanical properties, and topography. In this Review, we summarize key features of the GBM microenvironment and discuss different strategies for the engineering of GBM TME models, including 2D and 3D models featuring chemical and mechanical gradients, interfaces and fluid flow. Finally, we highlight the potential of engineered TME models as platforms for mechanistic discovery and drug screening as well as preclinical testing and precision medicine.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Cellular Mechanics and Interactions · Glioma Diagnosis and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united states in 2011–2015. Neuro. Oncol. 20, iv1–iv86 (2018).10.1093/neuonc/noy131 ↗
2. Koshy, M. et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J. Neurooncol. 107, 207–212 (2012).10.1007/s11060-011-0738-7 ↗
3. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).10.1016/S1470-2045(09)70025-7 ↗
4. Watanabe, M., Tanaka, R. & Takeda, N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 34, 463–469 (1992).10.1007/BF00598951 ↗
5. Young, R. M., Jamshidi, A., Davis, G. & Sherman, J. H. Current trends in the surgical management and treatment of adult glioblastoma. Ann. Transl. Med. 3, 121 (2015).
6. Sherriff, J. et al. Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. Br. J. Radiol. 86, 20120414 (2013).10.1259/bjr.20120414 ↗
7. Eyler, C. E. & Rich, J. N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 26, 2839–2845 (2008).10.1200/JCO.2007.15.1829 ↗
8. Franceschi, E. et al. Treatment options for recurrent glioblastoma: pitfalls and future trends. Expert Rev. Anticancer. Ther. 9, 613–619 (2009).10.1586/era.09.23 ↗
9. Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell 31, 326–341 (2017).10.1016/j.ccell.2017.02.009 ↗
10. Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891–906 (2009).10.1016/j.cell.2009.10.027 ↗
11. Nakasone, E. S. et al. Imaging tumor–stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21, 488–503 (2012).10.1016/j.ccr.2012.02.017 ↗
12. Ghajar, C. M. et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 15, 807–817 (2013).10.1038/ncb2767 ↗
13. Provenzano, P. P., Inman, D. R., Eliceiri, K. W. & Keely, P. J. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK–ERK linkage. Oncogene 28, 4326–4343 (2009).10.1038/onc.2009.299 ↗
14. Elahi-Gedwillo, K. Y., Carlson, M., Zettervall, J. & Provenzano, P. P. Antifibrotic therapy disrupts stromal barriers and modulates the immune landscape in pancreatic ductal adenocarcinoma. Cancer Res. 79, 372–386 (2019).10.1158/0008-5472.CAN-18-1334 ↗
15. Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418–429 (2012).10.1016/j.ccr.2012.01.007 ↗
16. De Vleeschouwer, S. & Bergers, G. in Glioblastoma Ch. 16 (ed De Vleeschouwer, S.) (Codon Publications, 2017).10.15586/codon.glioblastoma.2017 ↗
17. Jain, A. et al. Guiding intracortical brain tumour cells to an extracortical cytotoxic hydrogel using aligned polymeric nanofibres. Nat. Mater. 13, 308–316 (2014).10.1038/nmat3878 ↗
18. Gritsenko, P. G., Ilina, O. & Friedl, P. Interstitial guidance of cancer invasion. J. Pathol. 226, 185–199 (2012).10.1002/path.3031 ↗
19. Bellail, A. C., Hunter, S. B., Brat, D. J., Tan, C. & Van Meir, E. G. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int. J. Biochem. Cell Biol. 36, 1046–1069 (2004).10.1016/j.biocel.2004.01.013 ↗
20. van Tellingen, O. et al. Overcoming the blood–brain tumor barrier for effective glioblastoma treatment. Drug Resist. Updat. 19, 1–12 (2015).10.1016/j.drup.2015.02.002 ↗
21. de Vries, N. A., Beijnen, J. H., Boogerd, W. & van Tellingen, O. Blood–brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev. Neurother. 6, 1199–1209 (2006).10.1586/14737175.6.8.1199 ↗
22. Nimsky, C. et al. Preoperative and intraoperative diffusion tensor imaging-based fiber tracking in glioma surgery. Neurosurg. 56, 130–138 (2005).10.1227/01.NEU.0000144842.18771.30 ↗
23. Giese, A. & Westphal, M. Glioma invasion in the central nervous system. Neurosurg. 39, 235–252 (1996).10.1097/00006123-199608000-00001 ↗
24. Miller, K., Chinzei, K., Orssengo, G. & Bednarz, P. Mechanical properties of brain tissue in-vivo: experiment and computer simulation. J. Biomech. 33, 1369–1376 (2000).10.1016/S0021-9290(00)00120-2 ↗
25. Budday, S. et al. Mechanical properties of gray and white matter brain tissue by indentation. J. Mech. Behav. Biomed. Mater. 46, 318–330 (2015).10.1016/j.jmbbm.2015.02.024 ↗
26. Bernstein, J. J. & Woodard, C. A. Glioblastoma cells do not intravasate into blood vessels. Neurosurg. 36, 124–132 (1995).10.1227/00006123-199501000-00016 ↗
27. Nakod, P. S., Kim, Y. & Rao, S. S. Biomimetic models to examine microenvironmental regulation of glioblastoma stem cells. Cancer Lett. 429, 41–53 (2018).10.1016/j.canlet.2018.05.007 ↗
28. Lenting, K., Verhaak, R., ter Laan, M., Wesseling, P. & Leenders, W. Glioma: experimental models and reality. Acta Neuropathol. 133, 263–282 (2017).10.1007/s00401-017-1671-4 ↗
29. Xiao, W., Sohrabi, A. & Seidlits, S. K. Integrating the glioblastoma microenvironment into engineered experimental models. Future Sci. OA 3, FSO189 (2017).10.4155/fsoa-2016-0094 ↗
30. Novak, U. & Kaye, A. H. Extracellular matrix and the brain: components and function. J. Clin. Neurosci. 7, 280–290 (2000).10.1054/jocn.1999.0212 ↗
31. Zimmermann, D. R. & Dours-Zimmermann, M. T. Extracellular matrix of the central nervous system: from neglect to challenge. Histochem. Cell Biol. 130, 635–653 (2008).10.1007/s00418-008-0485-9 ↗
32. Bertolotto, A., Magrassi, M. L., Orsi, L., Sitia, C. & Schiffer, D. Glycosaminoglycan changes in human gliomas. A biochemical study. J. Neurooncol. 4, 43–48 (1986).10.1007/BF02158001 ↗
33. Chintala, S. K., Sawaya, R., Gokaslan, Z. L., Fuller, G. & Rao, J. S. Immunohistochemical localization of extracellular matrix proteins in human glioma, both in vivo and in vitro. Cancer Lett. 101, 107–114 (1996).10.1016/0304-3835(96)04124-9 ↗
34. Mahesparan, R. et al. Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol. 105, 49–57 (2003).10.1007/s00401-002-0610-0 ↗
35. Cowman, M. K., Lee, H.-G., Schwertfeger, K. L., McCarthy, J. B. & Turley, E. A. The content and size of hyaluronan in biological fluids and tissues. Front. Immunol. 6, 261 (2015).10.3389/fimmu.2015.00261 ↗
36. Dicker, K. T. et al. Hyaluronan: A simple polysaccharide with diverse biological functions. Acta Biomater. 10, 1558–1570 (2014).10.1016/j.actbio.2013.12.019 ↗
37. Akiyama, Y. et al. Hyaluronate receptors mediating glioma cell migration and proliferation. J. Neurooncol. 53, 115–127 (2001).10.1023/A:1012297132047 ↗
38. Breyer, R. et al. Disruption of intracerebral progression of rat C6 glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody. J. Neurosurg. 62, 140–149 (2000).10.3171/jns.2000.92.1.0140 ↗
39. Ponta, H., Sherman, L. & Herrlich, P. A. CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 4, 33–45 (2003).10.1038/nrm1004 ↗
40. Delpech, B. et al. Hyaluronan and hyaluronectin in the extracellular matrix of human brain tumour stroma. Eur. J. Cancer 29A, 1012–1017 (1993).10.1016/S0959-8049(05)80214-X ↗
41. Yoo, K.-C. et al. Proinvasive extracellular matrix remodeling in tumor microenvironment in response to radiation. Oncogene 37, 3317–3328 (2018).10.1038/s41388-018-0199-y ↗
42. Valkonen, M. et al. Elevated expression of hyaluronan synthase 2 associates with decreased survival in diffusely infiltrating astrocytomas. BMC Cancer 18, 664 (2018).10.1186/s12885-018-4569-1 ↗
43. Tian, X. et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature 499, 346–349 (2013).10.1038/nature12234 ↗
44. Chanmee, T., Ontong, P. & Itano, N. Mini-review. Hyaluronan: a modulator of the tumor microenvironment. Cancer Lett. 375, 20–30 (2016).10.1016/j.canlet.2016.02.031 ↗
45. Chen, J.-W. E. et al. Influence of hyaluronic acid transitions in tumor microenvironment on glioblastoma malignancy and invasive behavior. Front. Mater 5, 39 (2018).10.3389/fmats.2018.00039 ↗
46. Gladson, C. L. The extracellular matrix of gliomas: modulation of cell function. J. Neuropathol. Exp. Neurol. 58, 1029–1040 (1999).10.1097/00005072-199910000-00001 ↗
47. Ljubimova, J. Y., Fujita, M., Khazenzon, N. M., Ljubimov, A. V. & Black, K. L. Changes in laminin isoforms associated with brain tumor invasion and angiogenesis. Front. Biosci. 11, 81–88 (2006).10.2741/1781 ↗
48. Gamble, J. T. et al. Quantification of glioblastoma progression in zebrafish xenografts: Adhesion to laminin alpha 5 promotes glioblastoma microtumor formation and inhibits cell invasion. Biochem. Biophys. Res. Commun. 506, 833–839 (2018).10.1016/j.bbrc.2018.10.076 ↗
49. Lathia, J. D. et al. Laminin alpha 2 enables glioblastoma stem cell growth. Ann. Neurol. 72, 766–778 (2012).10.1002/ana.23674 ↗
50. Lathia, J. D. et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6, 421–432 (2010).10.1016/j.stem.2010.02.018 ↗
51. Shannon, S. et al. Dexamethasone-mediated activation of fibronectin matrix assembly reduces dispersal of primary human glioblastoma cells. PLoS One 10, e0135951 (2015).10.1371/journal.pone.0135951 ↗
52. Serres, E. et al. Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice. Oncogene 33, 3451–3462 (2014).10.1038/onc.2013.305 ↗
53. Sabari, J. et al. Fibronectin matrix assembly suppresses dispersal of glioblastoma cells. PLoS One 6, e24810 (2011).10.1371/journal.pone.0024810 ↗
54. Yuan, L. et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 26, 2563–2573 (2007).10.1038/sj.onc.1210048 ↗
55. Ogawa, K., Oguchi, M., Nakashima, Y. & Yamabe, H. Distribution of collagen Type IV in brain tumors: An immunohistochemical study. J. Neurooncol. 7, 357–366 (1989).10.1007/BF02147093 ↗
56. Rojiani, A. M. & Dorovini-Zis, K. Glomeruloid vascular structures in glioblastoma multiforme: an immunohistochemical and ultrastructural study. J. Neurosurg. 85, 1078–1084 (1996).10.3171/jns.1996.85.6.1078 ↗
57. Pointer, K. B. et al. Association of collagen architecture with glioblastoma patient survival. J Neurosurg 126, 1812–1821 (2017).10.3171/2016.6.JNS152797 ↗
58. Rauch, U. Brain matrix: structure, turnover and necessity. Biochem. Soc. Trans. 35, 656–660 (2007).10.1042/BST0350656 ↗
59. Lundell, A. et al. Structural basis for interactions between tenascins and lectican C-type lectin domains: evidence for a crosslinking role for tenascins. Structure 12, 1495–1506 (2004).10.1016/j.str.2004.05.021 ↗
60. Miroshnikova, Y. A. et al. Tissue mechanics promote IDH1-dependent HIF1α–tenascin C feedback to regulate glioblastoma aggression. Nat. Cell Biol. 18, 1336–1345 (2016).10.1038/ncb3429 ↗
61. Mirzaei, R. et al. Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Oncoimmunology 7, e1478647 (2018).10.1080/2162402X.2018.1478647 ↗
62. Sarkar, S., Nuttall, R. K., Liu, S., Edwards, D. R. & Yong, V. W. Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res. 66, 11771–11780 (2006).10.1158/0008-5472.CAN-05-0470 ↗
63. Rascher, G. et al. Extracellular matrix and the blood–brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol. 104, 85–91 (2002).10.1007/s00401-002-0524-x ↗
64. Pen, A., Moreno, M. J., Martin, J. & Stanimirovic, D. B. Molecular markers of extracellular matrix remodeling in glioblastoma vessels: microarray study of laser-captured glioblastoma vessels. Glia 55, 559–572 (2007).10.1002/glia.20481 ↗
65. Pietras, A. et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 14, 357–369 (2014).10.1016/j.stem.2014.01.005 ↗
66. Wei, J. et al. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J. Clin. Invest. 129, 137–149 (2018).10.1172/JCI121266 ↗
67. Lamour, V. et al. Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo. Int. J. Cancer 137, 1047–1057 (2015).10.1002/ijc.29454 ↗
68. Oyinlade, O. et al. Targeting UDP-α-d-glucose 6-dehydrogenase inhibits glioblastoma growth and migration. Oncogene 37, 2615–2629 (2018).10.1038/s41388-018-0138-y ↗
69. Chauvet, D. et al. In vivo measurement of brain tumor elasticity using intraoperative shear wave elastography. Eur. J. Ultrasound 37, 584–590 (2015).
70. Stewart, D. C., Rubiano, A., Dyson, K. & Simmons, C. S. Mechanical characterization of human brain tumors from patients and comparison to potential surgical phantoms. PLoS One 12, e0177561 (2017).
71. Ciasca, G. et al. Nano-mechanical signature of brain tumours. Nanoscale 8, 19629–19643 (2016).10.1039/C6NR06840E ↗
72. Ulrich, T. A. et al. The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res. 69, 4167–4174 (2009).10.1158/0008-5472.CAN-08-4859 ↗
73. Thomas, T. W. & DiMilla, P. A. Spreading and motility of human glioblastoma cells on sheets of silicone rubber depend on substratum compliance. Med. Biol. Eng. Comput. 38, 360–370 (2000).10.1007/BF02347059 ↗
74. Grundy, T. J. et al. Differential response of patient-derived primary glioblastoma cells to environmental stiffness. Sci. Rep. 6, 23353 (2016).10.1038/srep23353 ↗
75. Wong, S. Y. et al. Constitutive activation of myosin-dependent contractility sensitizes glioma tumor-initiating cells to mechanical inputs and reduces tissue invasion. Cancer Res. 75, 1113–1122 (2015).10.1158/0008-5472.CAN-13-3426 ↗
76. Ruiz-Ontañon, P. et al. Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue. Stem Cells 31, 1075–1085 (2013).10.1002/stem.1349 ↗
77. Kim, Y. & Kumar, S. CD44-mediated adhesion to hyaluronic acid contributes to mechanosensing and invasive motility. Mol. Cancer Res. 12, 1416–1429 (2014).10.1158/1541-7786.MCR-13-0629 ↗
78. Umesh, V., Rape, A. D., Ulrich, T. A. & Kumar, S. Microenvironmental stiffness enhances glioma cell proliferation by stimulating epidermal growth factor receptor signaling. PLoS One 9, e101771 (2014).10.1371/journal.pone.0101771 ↗
79. Mammoto, T. et al. Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression. Am. J. Pathol. 183, 1293–1305 (2013).10.1016/j.ajpath.2013.06.026 ↗
80. Seano, G. et al. Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. Nat. Biomed. Eng. 3, 230–245 (2019).10.1038/s41551-018-0334-7 ↗
81. Watkins, S. et al. Disruption of astrocyte–vascular coupling and the blood–brain barrier by invading glioma cells. Nat. Commun. 5, 4196 (2014).10.1038/ncomms5196 ↗
82. Candiello, J. et al. Biomechanical properties of native basement membranes. FEBS J. 274, 2897–2908 (2007).10.1111/j.1742-4658.2007.05823.x ↗
83. Charles, N. & Holland, E. C. The perivascular niche microenvironment in brain tumor progression. Cell Cycle 9, 3012–3021 (2010).10.4161/cc.9.15.12710 ↗
84. Giese, A. et al. Migration of human glioma cells on myelin. Neurosurg. 38, 755–764 (1996).10.1227/00006123-199604000-00026 ↗
85. Hensel, T., Amberger, V. & Schwab, M. A metalloprotease activity from C6 glioma cells inactivates the myelin-associated neurite growth inhibitors and can be neutralized by antibodies. Br. J. Cancer 78, 1564–1572 (1998).10.1038/bjc.1998.724 ↗
86. Amberger, V. R., Hensel, T., Ogata, N. & Schwab, M. E. Spreading and migration of human glioma and rat C6 cells on central nervous system myelin in vitro is correlated with tumor malignancy and involves a metalloproteolytic activity. Cancer Res. 58, 149–158 (1998).
87. Oellers, P., Schröer, U., Senner, V., Paulus, W. & Thanos, S. ROCKs are expressed in brain tumors and are required for glioma-cell migration on myelinated axons. Glia 57, 499–509 (2009).10.1002/glia.20777 ↗
88. Wang, J. et al. Invasion of white matter tracts by glioma stem cells is regulated by a NOTCH1–SOX2 positive-feedback loop. Nat. Neurosci. 22, 91–105 (2019).10.1038/s41593-018-0285-z ↗
89. Balzer, E. M. et al. Physical confinement alters tumor cell adhesion and migration phenotypes. FASEB J. 26, 4045–4056 (2012).10.1096/fj.12-211441 ↗
90. Monzo, P. et al. Mechanical confinement triggers glioma linear migration dependent on formin FHOD3. Mol. Biol. Cell 27, 1246–1261 (2016).10.1091/mbc.E15-08-0565 ↗
91. Heldin, C.-H., Rubin, K., Pietras, K., Ostman, A. & Östman, A. High interstitial fluid pressure — an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806–813 (2004).10.1038/nrc1456 ↗
92. Swartz, M. A. & Fleury, M. E. Interstitial flow and its effects in soft tissues. Annu. Rev. Biomed. Eng. 9, 229–256 (2007).10.1146/annurev.bioeng.9.060906.151850 ↗
93. Abbott, N. J. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem. Int. 45, 545–552 (2004).10.1016/j.neuint.2003.11.006 ↗
94. Geer, C. P. & Grossman, S. A. Interstitial fluid flow along white matter tracts: A potentially important mechanism for the dissemination of primary brain tumors. J. Neurooncol. 32, 193–201 (1997).10.1023/A:1005761031077 ↗
95. Kingsmore, K. M. et al. Interstitial flow differentially increases patient-derived glioblastoma stem cell invasion via CXCR4, CXCL12, and CD44-mediated mechanisms. Integr. Biol. 8, 1246–1260 (2016).10.1039/c6ib00167j ↗
96. Munson, J. M., Bellamkonda, R. V. & Swartz, M. A. Interstitial flow in a 3D microenvironment increases glioma invasion by a CXCR4-dependent mechanism. Cancer Res. 73, 1536–1546 (2013).10.1158/0008-5472.CAN-12-2838 ↗
97. Cornelison, R. C., Brennan, C. E., Kingsmore, K. M. & Munson, J. M. Convective forces increase CXCR4-dependent glioblastoma cell invasion in GL261 murine model. Sci. Rep. 8, 17057 (2018).10.1038/s41598-018-35141-9 ↗
98. Monteiro, A., Hill, R., Pilkington, G. & Madureira, P. The role of hypoxia in glioblastoma invasion. Cells 6, 45 (2017).10.3390/cells6040045 ↗
99. Lee, C. G. et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565–5570 (2000).
100. Figueroa, J. et al. Exosomes from glioma-associated mesenchymal stem cells increase the tumorigenicity of glioma stem-like cells via transfer of miR-1587. Cancer Res. 77, 5808–5819 (2017).10.1158/0008-5472.CAN-16-2524 ↗